Generation Bio Co. (GBIO)
NASDAQ: GBIO · Real-Time Price · USD
0.4043
+0.0025 (0.62%)
May 20, 2025, 2:20 PM - Market open
Generation Bio Co. Employees
Generation Bio Co. had 115 employees as of December 31, 2024. The number of employees decreased by 59 or -33.91% compared to the previous year.
Employees
115
Change (1Y)
-59
Growth (1Y)
-33.91%
Revenue / Employee
$213,530
Profits / Employee
-$625,470
Market Cap
27.10M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 115 | -59 | -33.91% |
| Dec 31, 2023 | 174 | 24 | 16.00% |
| Dec 31, 2022 | 150 | 0 | - |
| Dec 31, 2021 | 150 | 50 | 50.00% |
| Dec 31, 2020 | 100 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GBIO News
- 12 days ago - Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results - GlobeNewsWire
- 6 weeks ago - Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference - GlobeNewsWire
- 2 months ago - Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 3 months ago - Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 3 months ago - Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc. - Business Wire
- 4 months ago - Generation Bio to Apply ctLNP Delivery Technology to Develop siRNA Therapeutics for T Cell-Driven Autoimmune Diseases - GlobeNewsWire
- 7 months ago - Generation Bio Announces the Presentation of Preclinical Data on ctLNP and iqDNA at the ESGCT 31st Annual Congress - GlobeNewsWire
- 8 months ago - Generation Bio to Present at the 2024 Cantor Global Healthcare Conference - GlobeNewsWire